Autolus Therapeutics (AUTL) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL)
May 20, 2024 6:43 AM EDTWells Fargo analyst Yanan Zhu reiterated an Overweight rating and $8.00 price target on Autolus Therapeutics plc (NASDAQ: AUTL).
The analyst comments "We continue to see AUTL as well positioned for upside on 2H24 catalysts incl. B-ALL PDUFA (11/16) and first SLE data (late... More
